Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use REVUFORJ safely and effectively. See full prescribing information for REVUFORJ. Revuforj (revumenib) tablets for oral use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
Relapsed or Refractory Acute Leukemia REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
- generic_name
- revumenib
- product_names
- revumenib
- ndc
- 73555-500, 73555-500-00, 73555-501, 73555-501-00, 73555-502, 73555-502-00
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en